Efficacy and Safety of the CG-100 Intraluminal Bypass Device
Efficacy and Safety of the CG-100 Intraluminal Bypass Device in Colorectal and Coloanal Anastomoses: Prospective, Open Label, Randomized Trial
Sponsor: Colospan Ltd.
This NA trial investigates Rectal Cancer and Rectal Tumor and is currently actively recruiting participants. Colospan Ltd. leads this study, which shows 17 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Nov 2025 — Present [monthly]
Recruiting NA
Status: Withheld → Recruiting · Phase: None → NA
-
Oct 2025 — Nov 2025 [monthly]
Withheld
-
Sep 2024 — Oct 2025 [monthly]
Withheld
-
Sep 2022 — Sep 2024 [monthly]
Withheld
-
Jul 2022 — Sep 2022 [monthly]
Withheld
▶ Show 12 earlier versions
-
Apr 2022 — Jul 2022 [monthly]
Withheld
Status: Recruiting → Withheld · Phase: NA → None
-
Jan 2022 — Apr 2022 [monthly]
Recruiting NA
-
Dec 2021 — Jan 2022 [monthly]
Recruiting NA
-
Sep 2021 — Dec 2021 [monthly]
Recruiting NA
Status: Withheld → Recruiting · Phase: None → NA
-
May 2021 — Sep 2021 [monthly]
Withheld
-
Apr 2021 — May 2021 [monthly]
Withheld
-
Mar 2021 — Apr 2021 [monthly]
Withheld
-
Feb 2021 — Mar 2021 [monthly]
Withheld
-
Jan 2021 — Feb 2021 [monthly]
Withheld
-
Oct 2020 — Jan 2021 [monthly]
Withheld
-
Aug 2020 — Oct 2020 [monthly]
Withheld
-
Jan 2020 — Aug 2020 [monthly]
Withheld
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Colospan Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .